Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.57 |
| ▸ | FLT3 | P36888 | 9/20 | 0.57 |
| ▸ | FLT4 | P35916 | 4/20 | 0.57 |
| ▸ | KIT | P10721 | 2/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | MET | P08581 | 1/20 | 0.55 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.55 |
| ▸ | EGFR | P00533 | 4/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4467534 | 0.85 | KDR (0.73) | KDRFLT3FLT4KITPDGFRB | |
| SCHEMBL3718409 | 0.85 | KDR (0.73) | KDRFLT3FLT4KITPDGFRB | |
| SCHEMBL4481350 | 0.83 | KDR (0.58) | KDRFLT3FLT4KITPDGFRB | |
| SCHEMBL3719311 | 0.83 | KDR (0.60) | KDRFLT3FLT4KITPDGFRB | |
| SCHEMBL4461111 | 0.83 | KDR (0.73) | KDRFLT3FLT4KITPDGFRB | |
| SCHEMBL3718713 | 0.83 | KDR (0.73) | KDRFLT3FLT4KITPDGFRB | |
| SCHEMBL4463670 | 0.83 | KDR (0.60) | KDRFLT3FLT4KITPDGFRB | |
| SCHEMBL4461474 | 0.83 | KDR (0.57) | KDRFLT3FLT4KITPDGFRB | |
| SCHEMBL3720874 | 0.83 | KDR (0.57) | KDRFLT3FLT4KITPDGFRB | |
| SCHEMBL3798591 | 0.81 | KDR (0.70) | KDRFLT3FLT4KITPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572924-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, PLK2, PNCK | KDR 1387/4885FLT3 717/4885FLT4 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.